Aurobindo Pharma remained in focus after two major brokerages, HSBC and CLSA, issued positive views on the stock following its Q2FY26 performance. HSBC maintained a buy call with a target price of ₹1,315 per share, noting that while the quarter was operationally in line, profit after tax missed estimates due to higher taxes. The brokerage said reducing losses at new plants helped improve margins and added that clarity on the minimum import price for Pen G remains a key catalyst for the stock.
Meanwhile, CLSA reiterated its outperform call with a target price of ₹1,340 per share. The brokerage highlighted that Aurobindo Pharma’s Q2 revenue was in line with expectations, though PAT missed on margin pressures. It pointed out that strong growth in Europe offset weakness in the US and API segments. CLSA said it continues to maintain its FY26 revenue and margin guidance.
At the time of the reports, Aurobindo Pharma shares were trading at ₹1,135 on the exchange.
Disclaimer: The views and target prices mentioned are those of the brokerage firms (HSBC and CLSA). This article is for informational purposes only and does not constitute investment advice.
